Cyclolab's Dexolve in Gilead's patent application

News 3 November, 2017
A patent application from Gilead Sciences Inc (CA, USA) on Intravenous Formulations of a late sodium current inhibitor has been publshed recently. The patent application specifically names Cyclolab's Dexolve under its claims as the main formulating excipient. The formulation is suitable for treat several cardiovascular diseases.